Login to Your Account



Bioniche to Get up to $130M in Urology Deal with Endo

By Catherine Hollingsworth


Monday, July 13, 2009
Canadian biopharmaceutical firm Bioniche Life Sciences Inc. has entered a urology drug deal with U.S-based Endo Pharmaceuticals worth up to $130 million, essentially eliminating the company's cash burn for its bladder cancer program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription